Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01215916 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study in Patients With Solid Tumors
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT01215916 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 39 participants.
The verdict
NCT01215916, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the maximum tolerated dose (MTD) regimen for the combination therapy of LY573636 and pemetrexed that may be safely administered to patients with a solid tumor that is not amenable to curative therapy.
Interventions
- DRUG Pemetrexed
- DRUG LY573636
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2008-02 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01215916
The ClinicalTrials.gov registry entry for NCT01215916 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pemetrexed is the first listed.
NCT01215916 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01215916 about?
NCT01215916 is a clinical study titled "A Phase 1 Study in Patients With Solid Tumors". The primary objective of this study is to determine the maximum tolerated dose (MTD) regimen for the combination therapy of LY573636 and pemetrexed that may be safely administered to patients with a solid tumor that is not amenable to curative therapy.
What is the current status of trial NCT01215916?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2008-02. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01215916?
The interventions under investigation include: Pemetrexed (DRUG), LY573636 (DRUG).
Who is sponsoring clinical trial NCT01215916?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.